©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Orthop. Apr 18, 2024; 15(4): 312-317
Published online Apr 18, 2024. doi: 10.5312/wjo.v15.i4.312
Published online Apr 18, 2024. doi: 10.5312/wjo.v15.i4.312
Expandable endoprostheses in skeletally immature patients: Where we are
Recep Öztürk, Tumororthopädie und Sarkomchirurgie, Universitätsklinikum Essen, Essen 45143, Germany
Author contributions: Öztürk R, designed the study; performed the research; analyzed the data and wrote the manuscript.
Conflict-of-interest statement: The author stated that there is no conflict of interest.
Corresponding author: Recep Öztürk, MD, Associate Professor, Researcher, Surgeon, Surgical Oncologist, Tumororthopädie und Sarkomchirurgie, Universitätsklinikum Essen, Hufeland
Received: November 3, 2023
Peer-review started: November 3, 2023
First decision: January 12, 2024
Revised: January 26, 2024
Accepted: March 15, 2024
Article in press: March 15, 2024
Published online: April 18, 2024
Processing time: 164 Days and 11.1 Hours
Peer-review started: November 3, 2023
First decision: January 12, 2024
Revised: January 26, 2024
Accepted: March 15, 2024
Article in press: March 15, 2024
Published online: April 18, 2024
Processing time: 164 Days and 11.1 Hours
Core Tip
Core Tip: Extendable endoprosthesis replacements have been improved over the years and are now an established and safe alternative. Noninvasive prostheses appear to be advantageous compared to minimally invasive expandable prostheses that require multiple surgical procedures, but the complication rate remains high. Due to reported high complication rates, the procedures require significant experience and are recommended for use only in specialized cancer centers.